BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BridgeBio Pharma, Inc. (NASDAQ:BBIO) has been given an average rating of “Moderate Buy” by the twenty-three research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and twenty-two have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $81.55.

BBIO has been the subject of several research reports. The Goldman Sachs Group raised their price target on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Piper Sandler raised their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Cantor Fitzgerald boosted their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. JPMorgan Chase & Co. increased their price objective on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th.

Insider Activity

In other news, Director Andrew Lo sold 55,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total transaction of $3,612,950.00. Following the sale, the director owned 50,583 shares in the company, valued at $3,322,797.27. This represents a 52.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the transaction, the chief accounting officer directly owned 130,297 shares of the company’s stock, valued at $9,675,855.22. This represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 300,700 shares of company stock worth $21,034,671. Corporate insiders own 18.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Strs Ohio lifted its stake in BridgeBio Pharma by 1.1% in the 3rd quarter. Strs Ohio now owns 18,600 shares of the company’s stock valued at $966,000 after purchasing an additional 200 shares during the last quarter. GAMMA Investing LLC raised its stake in BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after buying an additional 227 shares during the period. Steward Partners Investment Advisory LLC lifted its position in shares of BridgeBio Pharma by 22.3% in the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock valued at $54,000 after buying an additional 228 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock worth $396,000 after acquiring an additional 244 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in shares of BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after acquiring an additional 245 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Price Performance

BBIO opened at $75.25 on Tuesday. The company has a market capitalization of $14.50 billion, a price-to-earnings ratio of -18.00 and a beta of 1.13. The business’s 50-day moving average price is $75.60 and its two-hundred day moving average price is $63.20. BridgeBio Pharma has a 1 year low of $28.33 and a 1 year high of $84.94.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.